APA (7th ed.) Citation

Espié, P., He, Y., Koo, P., Sickert, D., Dupuy, C., Chokoté, E., . . . Gergely, P. (2020). First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody. American journal of transplantation, 20(2), 463-473. https://doi.org/10.1111/ajt.15661

Chicago Style (17th ed.) Citation

Espié, Pascal, et al. "First‐in‐human Clinical Trial to Assess Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Iscalimab, an Anti‐CD40 Monoclonal Antibody." American Journal of Transplantation 20, no. 2 (2020): 463-473. https://doi.org/10.1111/ajt.15661.

MLA (9th ed.) Citation

Espié, Pascal, et al. "First‐in‐human Clinical Trial to Assess Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Iscalimab, an Anti‐CD40 Monoclonal Antibody." American Journal of Transplantation, vol. 20, no. 2, 2020, pp. 463-473, https://doi.org/10.1111/ajt.15661.